INmune Bio Inc.
INMB
$1.23
$0.010.82%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 50.00K | 50.00K | 50.00K | 50.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 50.00K | 50.00K | 50.00K | 50.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 50.00K | 50.00K | 50.00K | 50.00K |
| SG&A Expenses | 10.02M | 10.17M | 9.24M | 8.82M | 9.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.78M | 30.92M | 34.91M | 39.77M | 41.57M |
| Operating Income | -26.78M | -30.87M | -34.86M | -39.72M | -41.52M |
| Income Before Tax | -41.60M | -45.93M | -49.89M | -55.51M | -40.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.60 | -45.93 | -49.89 | -55.51 | -40.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.60M | -45.93M | -49.89M | -55.51M | -40.80M |
| EBIT | -26.78M | -30.87M | -34.86M | -39.72M | -41.52M |
| EBITDA | -18.60M | -12.84M | -7.42M | -- | -- |
| EPS Basic | -1.69 | -1.92 | -2.14 | -2.50 | -1.95 |
| Normalized Basic EPS | -0.63 | -0.77 | -0.91 | -1.12 | -1.22 |
| EPS Diluted | -1.69 | -1.92 | -2.14 | -2.50 | -1.95 |
| Normalized Diluted EPS | -0.63 | -0.77 | -0.91 | -1.12 | -1.22 |
| Average Basic Shares Outstanding | 103.07M | 98.99M | 94.63M | 88.23M | 84.24M |
| Average Diluted Shares Outstanding | 103.07M | 98.99M | 94.63M | 88.23M | 84.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |